This poster proposes the development of a MCS based on processing route. This is intended as a tool for pharmaceutical scientists to rank the feasibility of different processing routes for the manufacture of oral solid dosage forms, based on selected properties of the API and the needs of the formulation. The proposed MCS could be used to develop a risk assessment for manufacturing and also indicate how robust a manufacturing process is likely to be. The MCS will have many applications in pharmaceutical development: in particular, it would provide a common understanding of risk, define what are the "right particles" and best process, and aid subsequent transfer to manufacturing. The ultimate aim would be one of prediction from previous experience. This approach fits with Quality by Design (QBD) principles and has the potential of obtaining regulatory relief on the development of dosage forms by demonstrating that the properties of the ingoing API and excipients are within established ranges for the manufacturing process. Furthermore, this MCS has potential to reduce the incidence of late stage failure, thus saving resource. The proposal aims to provide a frame of reference for level of risk vs. process type. Two concepts in particular have been expanded upon: the first is to define API developability where the team has outlined the parameters and value ranges that define the recommended manufacturing class and the likelihood of successfully developing an oral solid dosage form. The second consideration is drug loading: as this increases, API properties have an increased influence on the formulation properties and processability. The team is proposing the use of percolation (impact) levels, which may vary across different attributes and parameters, to quantify this risk.
